Tag Archives: MNKD

what is the stock market

North Korea is faring relatively well despite China’s recent coal sanctions, thanks primarily to Russia lending a hand.

Indeed, as cracks continue to deepen in the decades-old friendship between Pyongyang and Beijing, Russian President Vladimir Putin has taken steps to fill in the Red Dragon’s shoes.

“Russia (has) begun quietly laying the groundwork that would strengthen its ties to North Korea, thus increasing its global political leverage should it need it,” analysts at political intelligence firm Stratfor explained in a May 5 report, referring to Putin’s overwrought ties with the West.

And just today (June 5), statistical proof emerged that this relationship is already flourishing…

Here’s how Russia is keeping Kim Jong Un’s kingdom afloat in spite of the international community’s tightening chokehold…

North Korea Sells Its Coal to Big Brother Russia

According to a USA Today report this morning, trade between Russia and North Korea increased by a staggering 73% during the first two months of this year compared to the same period last year.

what is the stock market: Brady Corporation(BRC)

Advisors’ Opinion:

  • [By Michael Flannelly]

    Before the opening bell on Thursday, identification solutions provider Brady Corp (BRC) posted a loss in the fourth quarter, despite a rise in revenues, as it was negatively impacted by a number of charges. However, excluding these charges, the company was able to top Wall Street analysts’ earnings and sales estimates. Nonetheless, BRC shares are plummeting in Thursday’s trading.

    The Milwaukee, Wisconsin-based company posted a loss from continuing operations of $176.2 million, or $3.41 per share, in the fourth quarter, versus last year’s fourth quarter earnings from continuing operations of $20.9 million, or 40 cents per share. Furthermore, Brady posted a net loss of $177.2 million, or $3.43 per share, compared to net earnings of $11.6 million, or 22 cents per share, in the same period a year ago.

    The fourth quarter loss includes non-cash impairment charges of $204.4 million, $15.6 million in restructuring charges, and $4 million in acquisition-related charges. Excluding these charges, Brady Corp said earnings would have been 53 cents per share in the quarter. According to analysts polled by Thomson Reuters, the company was expected to earn an adjusted 51 cents per share in the fourth quarter.

    The company’s fourth quarter sales came in at $309.1 million, up 15% from $269.1 million in sales posted last year. On average, analysts were expecting the company to see $307.13 million in revenues for the quarter.

    Looking ahead, Brady Corp. sees fiscal 2014 earnings coming in between $1.80 and $2.00 per share, below the analysts’ view of $2.30 per share.

    Brady Corp shares were down $1.71, or 5.25%, during early morning trading on Thursday. The stock is up 7.93% year-to-date.

  • [By Mike Deane]

    For the 28th year in a row, Brady Corp (BRC) has increased its dividend payout to investors.

    The Milwaukee, WI-based company increased its quarterly dividend to 19.5 cents from 19 cents, an increase of 2.6%. The annual dividend now stands at 78 cents. The quarterly dividend will be paid on October 31st, 2013 to all shareholders of record on October 10, 2013.

    BRC shares were down 40 cents, or 1.23%, by market close on Wednesday. YTD, the company’s stock is down over 4%.

  • [By Shauna O’Brien]

    Robert Baird announced on Friday that it has cut its rating on Brady Corp (BRC).

    The firm has downgraded BRC from “Outperform” to “Neutral,” and has given the company a $33 price target. This price target suggests a 8% upside from the stock’s current price of $30.52.

    Analysts see the company’s WPS segment growing faster than expected.

    Brady shares were mostly flat during pre-market trading Friday. The stock is down 9% YTD.

what is the stock market: Gold Standard Ventures Corporation(GSV)

Advisors’ Opinion:

  • [By Sara Cornell]

    The management team member who garners the most attention right now is Dave Mathewson, VP, Head of Exploration. Dave is a geologist with more than 35 years’ experience in the gold exploration space, and specifically, in Nevada. He is credited with a number of notable discoveries for Newmont Mining Corp (NYSE: NEM), and later went on to Gold Standard Ventures Corp (NYSE: GSV) helping take that company from a start-up to a now $481 million market cap.

what is the stock market: Turkcell Iletisim Hizmetleri AS(TKC)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, telecommunications services shares slipped by 0.08 percent. Meanwhile, top losers in the sector included Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE: TKC), down 2 percent, and Telefonica Brasil SA (ADR) (NYSE: VIV), down 2.5 percent.

what is the stock market: MannKind Corporation(MNKD)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap diabetes stock MannKind Corporation (NASDAQ: MNKD) reportedQ1 2017 earnings after the Thursday market close.The Companysnovel rapid-acting inhaled insulin therapy Afrezza has generally been a disappointment for investors with the stock havingelevated short interest of 38.86% according to Highshortinterest.com.

  • [By Peter Graham]

    The Q4 2016 earnings report for troubled small cap diabetes stock MannKind Corporation (NASDAQ: MNKD) is scheduled for after the market closes Thursday (March 16th). So far,MannKind Corporations novel rapid-acting inhaled insulin therapy Afrezza has been a disappointment for investors; and if that doesnt start to change, theMNKD could soon run out of money. For that reason, the Company has elevated short interest of 36.43% according to Highshortinterest.com.

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

  • [By Lisa Levin]

    MannKind Corporation (NASDAQ: MNKD) shares were also up, gaining 24 percent to $6.59. H.C. Wainwright initiated coverage on MannKind with a Buy rating and a $7.00 price target.

  • [By Sean Williams]

    Last summer, my mind was fully set on short-selling shares (i.e., betting they go down) of drugmaker MannKind (NASDAQ:MNKD). My investment thesis was pretty straightforward: MannKind was eventually going to seek bankruptcy protection.

best stocks to buy in

Engaging in an initial public offering is an often thrown around prospect in the financial markets, but unlike the IPO, Initial Coin Offerings are relatively new phenomena, which came about with the evolution of cryptocurrencies. Just as IPO fever ran high in the 1990s, there is now a flurry of activity on the ICO front.

Cryptocurrencies are forms of digital money designed to be secure and anonymous in most cases, which use a technology called cryptography.

About 900 cryptocurrencies are currently in active use.

ICO: Funding Route For Cryptocurrency Start Ups

The ICO is a way to fund cryptocurrency projects. It is an offering in which a new cryptocurrency project sells part of cryptocurrency tokens to investors in exchange for money, with the proceeds primarily raised in bitcoin or other cryptocurrencies, according to Smith & Crown.

best stocks to buy in: Liberty Interactive Corporation(LVNTA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of General Communication, Inc. (NASDAQ: GNCMA) got a boost, shooting up 63 percent to $33.43 after Liberty Interactive Corporation (NASDAQ: LVNTA) announced plans to acquire General Communication for $1.12 billion.

best stocks to buy in: Lucas Energy, Inc.(LEI)

Advisors’ Opinion:

  • [By Garrett Baldwin]

    The Interior Department is in charge of managing regulations around oil and gas drilling around the nation. Currently, the favorite appears to be Forrest Lucas, the 74-year-old founder of Lucas Energy Inc. (NYSEMKT: LEI). A career energy executive, Lucas recently told Investors Business Daily that he would be interested in the job because “it’s a very important position and you need to have someone in there who knows what they’re doing.” However, Lucas has never actually met Trump in person.

best stocks to buy in: Tableau Software, Inc.(DATA)

Advisors’ Opinion:

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Monday’s regular session.

    Pier 1 Imports Inc (NYSE: PIR) Dec16 5.0 Puts Sweep: 1191 @ ASK $0.80: 1354 traded vs 102 OI: $5.32 Ref
    Alcoa Inc (NYSE: AA) Jul16 9.5 Puts Sweep: 1494 @ ASK $0.13: 14k traded vs 6682 OI: $10.09 Ref
    Sarepta Therapeutics Inc (NASDAQ: SRPT) Jul16 10.0 Puts: 3536 @ ASK $0.50: 5506 traded vs 54k OI: Earnings 8/4 $22.50 Ref
    Tableau Software Inc (NYSE: DATA) Jul16 47.5 Puts Sweep: 837 @ ASK $0.30: 995 traded vs 37 OI: Earnings 8/3 $50.60 Ref
    Yandex NV (NASDAQ: YNDX) Aug16 18.0 Puts Sweep: 532 @ ASK $0.30: 2143 traded vs 78 OI: Earnings 7/28 Before Open $22.02 Ref
    Wolverine World Wide, Inc. (NYSE: WWW) Aug16 22.5 Puts: 719 @ ASK $1.35: 1032 traded vs 0 OI: Earnings 7/19 $22.22 Ref
    Conn's Inc (NASDAQ: CONN) Jan17 5.0 Puts Sweep: 605 @ ASK $0.85: 1355 traded vs 3132 OI: $7.16 Ref

    Posted-In: Huge Put PurchasesNews Options Markets

best stocks to buy in: Lee Enterprises, Incorporated(LEE)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, cyclical consumer goods & services shares rose by just 0.4 percent. Meanwhile, top losers in the sector included Titan International Inc (NYSE: TWI), down 13 percent, and Lee Enterprises, Incorporated (NYSE: LEE), down 4 percent.

  • [By Lisa Levin]

    Tuesday afternoon, the cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Beasley Broadcast Group Inc (NASDAQ: BBGI) and Lee Enterprises, Incorporated (NYSE: LEE).

best stocks to buy in: MannKind Corporation(MNKD)

Advisors’ Opinion:

  • [By Peter Graham]

    The Q4 2016 earnings report for troubled small cap diabetes stock MannKind Corporation (NASDAQ: MNKD) is scheduled for after the market closes Thursday (March 16th). So far,MannKind Corporations novel rapid-acting inhaled insulin therapy Afrezza has been a disappointment for investors; and if that doesnt start to change, theMNKD could soon run out of money. For that reason, the Company has elevated short interest of 36.43% according to Highshortinterest.com.

  • [By Sean Williams]

    Last summer, my mind was fully set on short-selling shares (i.e., betting they go down) of drugmaker MannKind (NASDAQ:MNKD). My investment thesis was pretty straightforward: MannKind was eventually going to seek bankruptcy protection.

  • [By Ben Levisohn]

    Hopes were high for MannKind (MNKD) when its inhaled insulin Afrezza was approved by the FDA more than two years ago. At the time, Barron’s warned that it was time to dump MannKind’s shares, something that now seems prescient, as its shares have since tumbled 95%. No wonder, as the news since then has been far from good. MannKind found a partner in Sanofi (SNY), only to get dumped in early 2016, and has since been forced to sell property to raise cash. And now MannKind could be on the verge of being delisted from the Nasdaq due to its sub $1 stock price. What now? Piper Jaffray’sJoshua Schimmer and team see a reverse stock split in MannKind’s future:

    [MannKind] has been focused on relaunch of Afrezza (inhaled insulin) for diabetes since Sanofi terminated its partnership for that program last year. Progress has been slow as the company first deployed a contract sales force but is now switching to an internal one. Hiring is nearly complete and reps will be out in the field soon. The company has also made strides in expanding reimbursement coverage for Afrezza. MannKind is also in the process of launching a new Titration Pack for Afrezza that allows for greater dosing flexibility in an attempt to simplify prescribing patterns of the drug. However with all these efforts, scrips have not yet shown signs of life in a very crowded diabetes market where MannKind is likely to struggle to claim share of voice relative to large pharma competitors. MannKind held a special meeting of stockholders in February 2017 in order to gain authority for a reverse stock split, if necessary to avoid de-listing by NASDAQ. MannKind recently indicated its cash position to be at ~$120M (and added $17M from the sale of its Valencia facility in February), which does provide some room to grow Afrezza sales before having to seek out yet another dilutive raise. However, its unclear if any of the new commercial efforts will help to rescue Afrezza sales. Ou

day trading software

This article is reprinted by permission from NextAvenue.org.

If you are like most people, when you hear the words estate planning, you probably think of writing a will, to explain who will get what you own when you die. The problem is, a will has little or nothing to do withyou. Its all about planning for someone else. In reality, estate planning is about much more than writing a will; its also about taking care ofyouwhile you are alive, should you become incapacitated and unable to make your own decisions.

day trading software: MannKind Corporation(MNKD)

Advisors’ Opinion:

  • [By James E. Brumley]

    When most investors think of diabetes stocks, names like Novo Nordisk A/S (ADR) (NYSE:NVO) and MannKind Corporation (NASDAQ:MNKD) come to mind. And well they should. Novo Nordisk is the biggest insulin company in the world, and while MannKind is relatively small, it’s a name that turns heads simply because it came up with an inhalable insulin that – after a slow start – is getting a little traction.

    In both cases though, the paradigm is the same one that was first used decades ago. That is, if a person isn’t making their own insulin, then it must be introduced externally. What if instead a diabetic’s glucose levels could be controlled by turning on the cells in their body responsible for processing that sugar? That’s the approach Cell MedX Corp (OTCMKTS:CMXC) is taking, using a relatively new but very compelling science.

    While chemical-based manufactured pharmaceuticals were largely the core of healthcare for well over the past century, it’s become clear that our bodies – right down to our cells – are also electrical in nature. Not only do they produce it, they need it to function properly. The FDA has even recently approved a therapeutic device that delivers mild electrical currents to and through an individual’s body as a means of treating pain. This “electromedicine” has also shown a certain degree of efficacy as a treatment for several illnesses, including cancer. Specifically, electrical currents have been demonstrated to force pleomorphic cancer microbes into hibernation, essentially making a cancerous cell a normal, healthy cell again. So, using an electrical current as a means of therapy for diabetics isn’t far-fetched at all. Indeed, it’s quite brilliant.

    As for how Cell MedX is using the idea, it’s actually quite simple. The device is called an eBalance. At first glance it just looks like another ordinary tablet computer. A closer inspection of the e-Balance device, however, makes it clear that it’s not just another tablet. It’

  • [By Sean Williams]

    Last summer, my mind was fully set on short-selling shares (i.e., betting they go down) of drugmaker MannKind (NASDAQ:MNKD). My investment thesis was pretty straightforward: MannKind was eventually going to seek bankruptcy protection.

  • [By Peter Graham]

    Small cap diabetes stock MannKind Corporation (NASDAQ: MNKD) reportedQ1 2017 earnings after the Thursday market close.The Companysnovel rapid-acting inhaled insulin therapy Afrezza has generally been a disappointment for investors with the stock havingelevated short interest of 38.86% according to Highshortinterest.com.

  • [By Lisa Levin]

    MannKind Corporation (NASDAQ: MNKD) shares were also up, gaining 24 percent to $6.59. H.C. Wainwright initiated coverage on MannKind with a Buy rating and a $7.00 price target.

  • [By WWW.MONEYSHOW.COM]

    MannKind Corp. (MNKD) has developed a drug, Afrezza, which is a new form of inhalable insulin that is proving to have many benefits over existing mealtime insulins for diabetics.  

  • [By Peter Graham]

    The Q4 2016 earnings report for troubled small cap diabetes stock MannKind Corporation (NASDAQ: MNKD) is scheduled for after the market closes Thursday (March 16th). So far,MannKind Corporations novel rapid-acting inhaled insulin therapy Afrezza has been a disappointment for investors; and if that doesnt start to change, theMNKD could soon run out of money. For that reason, the Company has elevated short interest of 36.43% according to Highshortinterest.com.

day trading software: Towerstream Corporation(TWER)

Advisors’ Opinion:

  • [By Lisa Levin]

    Towerstream Corporation (NASDAQ: TWER) shares were also up, gaining 9 percent to $3.49. Towerstream is scheduled to report Q2 financial results on August 9, 2016.

day trading software: Nord Anglia Education, Inc.(NORD)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Monday, our Under the Radar Moversnewsletter suggested going long on small cap international school stock Nord Anglia Education Inc (NYSE: NORD):

  • [By Lisa Levin]

    Nord Anglia Education Inc (NASDAQ: NORD) shares shot up 19 percent to $32.83 after the company agreed to be acquired for $32.50 per share in cash.

day trading software: CIRCOR International, Inc.(CIR)

Advisors’ Opinion:

  • [By Lisa Levin]

    CIRCOR International, Inc. (NYSE: CIR) was down, falling around 15 percent to $60.91. CIRCOR reported Q4 adjusted earnings of $0.48 per share on revenue of $158 million. Stifel Nicolaus downgraded Circor from Buy to Hold.

day trading software: Gartner, Inc.(IT)

Advisors’ Opinion:

  • [By Lisa Levin]

    CEB Inc. (NYSE: CEB) shares were also up, gaining 21 percent to $74.90 after Gartner Inc (NYSE: IT) announced plans to acquire the company for $2.6 billion in cash and stock.

day trading software: Signet Jewelers Limited(SIG)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was Signet Jewelers Limited (NYSE: SIG), which rose roughly 9% to $52.52. The stocks 52-week range is $46.09 to $101.46. Volume was nearly 5 million on the day compared to the average of 1.8 million.

  • [By Peter Graham]

    A long term performance chart shows shares of Tiffany & Co and small cap Blue Nile Inc (NASDAQ: NILE) nowback in positive territory and trending up while Signet Jewelers Ltd (NYSE: SIG) has outperformedbut that outperformancestarted falling off late last year:

  • [By WWW.THESTREET.COM]

    Earnings of note in the coming week include Analogic (ALOG) and Ascena Retail (ASNA) on Monday; Bojangles (BOJA) , H&R Block (HRB) , and Dick’s Sporting Goods (DKS) , Michaels (MIK) , and Urban Outfitters (URBN) on Tuesday; Ciena (CIEN) , Bankrate (RATE) , Express (EXPR) , Vera Bradley (VRA) , and Bob Evans Farms (BOBE) on Wednesday; El Pollo Loco (LOCO) , Hugo Boss (BOSSY) , Party City (PRTY) , Signet Jewelers (SIG) , and Verifone Systems (PAY) on Thursday; and Kirkland’s (KIRK) , and Vail Resorts (MTN) on Friday.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was Signet Jewelers Limited (NYSE: SIG) which jumped 8.8% to $70.06. The gain was following news that the company had a solid earnings report. The stocks 52-week range is $62.10 to $125.45. Volume was 7.48 million which is well above the daily average of around 1.69 million shares.